An Important Announcement from Blueprint Medicines & Ipsen

Ipsen and Blueprint enter exclusive agreement in FOP

We're pleased to share this news from Blueprint Medicines and Ipsen. This news does not change Ipsen’s commitment to developing palovarotene or BLU-782 as potential treatments for FOP. Visit Ipsen's website to read more.

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter